{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:18:19Z","timestamp":1790774299477,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["2201110367"],"award-info":[{"award-number":["2201110367"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012001","name":"Al Jalila Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bcp.2025.117535","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T16:09:47Z","timestamp":1762618187000},"page":"117535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P2","title":["Opposing outcomes of short- and long-term epigenetic therapy in breast cancer: Implications for chemotherapy response"],"prefix":"10.1016","volume":"243","author":[{"given":"Wafaa S","family":"Ramadan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragheb","family":"Alsheikh Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alqedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahia","family":"El-Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Al-Shihabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem Sami","family":"Alhamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Yener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat","family":"Hamoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7046-8587","authenticated-orcid":false,"given":"Raafat","family":"El-Awady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117535_b0005","series-title":"Epigenetics in Human Disease (third Edition)","first-page":"85","article-title":"Chapter 4 - Alterations of histone modifications in cancer","author":"Saber-Ayad","year":"2024"},{"issue":"11","key":"10.1016\/j.bcp.2025.117535_b0010","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet."},{"key":"10.1016\/j.bcp.2025.117535_b0015","article-title":"Long non-coding rnas in cancer: implications for diagnosis, prognosis, and therapy","volume":"7","author":"Qian","year":"2020","journal-title":"Front. Med. (lausanne)"},{"key":"10.1016\/j.bcp.2025.117535_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.bcp.2025.117535_b0025","doi-asserted-by":"crossref","first-page":"578","DOI":"10.2174\/138161213804581918","article-title":"Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives","volume":"19","author":"Andreoli","year":"2013","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.bcp.2025.117535_b0030","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1080\/15592294.2019.1640546","article-title":"Epidrugs: targeting epigenetic marks in cancer treatment","volume":"14","author":"Miranda Furtado","year":"2019","journal-title":"Epigenetics"},{"issue":"10","key":"10.1016\/j.bcp.2025.117535_b0035","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(17)30576-4","article-title":"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1\/2 trial","volume":"18","author":"Kantarjian","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.bcp.2025.117535_b0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0045","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13148-021-01069-7","article-title":"Advances in epigenetic therapeutics with focus on solid tumors","volume":"13","author":"Jin","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"2","key":"10.1016\/j.bcp.2025.117535_b0050","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2217\/epi.14.73","article-title":"Epigenetic therapy for solid tumors: from bench science to clinical trials","volume":"7","author":"Juo","year":"2015","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0055","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13148-015-0157-2","article-title":"Epigenetic treatment of solid tumours: a review of clinical trials","volume":"7","author":"Nervi","year":"2015","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.bcp.2025.117535_b0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cbpa.2020.04.008","article-title":"Towards a more precise therapy in cancer: Exploring epigenetic complexity","volume":"57","author":"Coss\u00edo","year":"2020","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2025.117535_b0065","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2025.117535_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113588","article-title":"Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapy","volume":"222","author":"Duan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bcp.2025.117535_b0075","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-13-0095","article-title":"Phase I trial of a new schedule of romidepsin in patients with advanced cancers","volume":"19","author":"Amiri-Kordestani","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bcp.2025.117535_b0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2217\/epi-2023-0142","article-title":"Role of epigenetic drugs in sensitizing cancers to anticancer therapies: emerging trends and clinical advancements","volume":"15","author":"Singh","year":"2023","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.bcp.2025.117535_b0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-019-0267-4","article-title":"Combining epigenetic drugs with other therapies for solid tumours \u2014 past lessons and future promise","volume":"17","author":"Morel","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2025.117535_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.177001","article-title":"Impact of HDAC6-mediated progesterone receptor expression on the response of breast cancer cells to hormonal therapy","volume":"983","author":"Ramadan","year":"2024","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0095","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13059-025-03528-3","article-title":"The histone acetyltransferase CBP participates in regulating the DNA damage response through ATM after double-strand breaks","volume":"26","author":"Ramadan","year":"2025","journal-title":"Genome Biol."},{"issue":"9","key":"10.1016\/j.bcp.2025.117535_b0100","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.3390\/ijms26094194","article-title":"Transcriptome-wide analysis and experimental validation from FFPE tissue identifies stage-specific gene expression profiles differentiating adenoma, carcinoma in-situ and adenocarcinoma in colorectal cancer progression","volume":"26","author":"Alhosani","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.bcp.2025.117535_b0105","doi-asserted-by":"crossref","first-page":"15065","DOI":"10.1021\/acs.jmedchem.5c01216","article-title":"Design, synthesis, and anticancer evaluation of novel MGBs with alkyne-linked thiazole moieties","volume":"68","author":"Msallam","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0110","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41467-019-09234-6","article-title":"Metascape provides a biologist-oriented resource for the analysis of systems-level datasets","volume":"10","author":"Zhou","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0115","doi-asserted-by":"crossref","first-page":"11432","DOI":"10.1038\/srep11432","article-title":"TRRUST: a reference database of human transcriptional regulatory interactions","volume":"5","author":"Han","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bcp.2025.117535_b0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/JP9.0000000000000024","article-title":"A note on error bars as a graphical representation of the variability of data in biomedical research: choosing between standard deviation and standard error of the mean","volume":"2","author":"Tang","year":"2019","journal-title":"J. Pancreatol."},{"issue":"10","key":"10.1016\/j.bcp.2025.117535_b0125","first-page":"1558","article-title":"Intermittent hypoxia changes HIF-1\u03b1 phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1\u03b1, Biochimica et Biophysica Acta (BBA) - Molecular","volume":"1773","author":"Toffoli","year":"2007","journal-title":"Cell Res."},{"issue":"1\u20132","key":"10.1016\/j.bcp.2025.117535_b0130","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.mce.2014.04.008","article-title":"Distinct roles of HIF1A in endothelial adaptations to physiological and ambient oxygen","volume":"391","author":"Jiang","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.bcp.2025.117535_b0135","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2025.117535_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122639","article-title":"Deciphering the interplay of histone post-translational modifications in cancer: co-targeting histone modulators for precision therapy","volume":"346","author":"Kawaf","year":"2024","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117535_b0145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7150\/thno.29520","article-title":"Epigenetic co-deregulation of EZH2\/TET1 is a senescence-countering, actionable vulnerability in triple-negative breast cancer","volume":"9","author":"Yu","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2025.117535_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109728","article-title":"H3K27me3 loss plays a vital role in CEMIP mediated carcinogenesis and progression of breast cancer with poor prognosis","volume":"123","author":"Hsieh","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"24","key":"10.1016\/j.bcp.2025.117535_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21249501","article-title":"No easy way out for EZH2: its pleiotropic, noncanonical effects on gene regulation and cellular function","volume":"21","author":"Wang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"13","key":"10.1016\/j.bcp.2025.117535_b0160","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1073\/pnas.1503152112","article-title":"STAT3-driven transcription depends upon the dimethylation of K49 by EZH2","volume":"112","author":"Dasgupta","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117535_b0165","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.molcel.2012.09.004","article-title":"EZH2 generates a methyl degron that is recognized by the DCAF1\/DDB1\/CUL4 E3 ubiquitin ligase complex","volume":"48","author":"Lee","year":"2012","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0170","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13072-018-0213-1","article-title":"EZH2 promotes DNA replication by stabilizing interaction of POL\u03b4 and PCNA via methylation-mediated PCNA trimerization","volume":"11","author":"Xu","year":"2018","journal-title":"Epigenetics Chromatin"},{"issue":"5","key":"10.1016\/j.bcp.2025.117535_b0175","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1186\/bcr2762","article-title":"Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility","volume":"12","author":"Leong","year":"2010","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41525-021-00232-6","article-title":"Loss of grand histone H3 lysine 27 trimethylation domains mediated transcriptional activation in esophageal squamous cell carcinoma","volume":"6","author":"Yuan","year":"2021","journal-title":"NPJ Genom. Med."},{"issue":"13","key":"10.1016\/j.bcp.2025.117535_b0185","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/0008-5472.CAN-13-3147","article-title":"Loss of the polycomb mark from bivalent promoters leads to activation of cancer-promoting genes in colorectal tumors","volume":"74","author":"Hahn","year":"2014","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0190","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.bbrc.2009.12.011","article-title":"DNA methylation-dependent suppression of HIF1A in an immature hematopoietic cell line HMC-1","volume":"391","author":"Walczak-Drzewiecka","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0195","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13046-020-01733-5","article-title":"Epigenetic crosstalk between hypoxia and tumor driven by HIF regulation","volume":"39","author":"Li","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0200","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1038\/s41467-022-31764-9","article-title":"Hypoxia induces HIF1\u03b1-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy","volume":"13","author":"Ma","year":"2022","journal-title":"Nat. Commun."},{"issue":"49","key":"10.1016\/j.bcp.2025.117535_b0205","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.1422015112","article-title":"Estrogen receptor-\u03b1 directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"43","key":"10.1016\/j.bcp.2025.117535_b0210","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035493","article-title":"Hypoxia-mediated activation of hypoxia-inducible factor-1\u03b1 in triple-negative breast cancer: a review","volume":"102","author":"Liu","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.bcp.2025.117535_b0215","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1158\/0008-5472.CAN-21-0871","article-title":"Loss of H3K27 trimethylation promotes radiotherapy resistance in medulloblastoma and induces an actionable vulnerability to BET inhibition","volume":"82","author":"Gabriel","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2025.117535_b0220","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s40478-023-01615-9","article-title":"Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis","volume":"11","author":"Cello","year":"2023","journal-title":"Acta Neuropathol. Commun."},{"issue":"8","key":"10.1016\/j.bcp.2025.117535_b0225","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1093\/neuonc\/noab036","article-title":"Loss of H3K27me3 in meningiomas","volume":"23","author":"Nassiri","year":"2021","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2025.117535_b0230","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1189\/jlb.6A0617-217R","article-title":"Differentiation stage-specific effect of histone deacetylase inhibitors on the expression of ROR\u03b3T in human lymphocytes","volume":"102","author":"Sa\u0142kowska","year":"2017","journal-title":"J. Leukoc. Biol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225008007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:20:47Z","timestamp":1781065247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225008007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"alternative-id":["S0006295225008007"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117535","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opposing outcomes of short- and long-term epigenetic therapy in breast cancer: Implications for chemotherapy response","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117535","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117535"}}